Reviewer's report

Title: Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review

Version: 0 Date: 21 Nov 2017

Reviewer: Andrew Beswick

Reviewer's report:

This is a well written and interesting review. Narrative reviews provide an introduction or overview of a topic and this serves the purpose well. While not a "systematic" review, the authors summarise good quality research and guidelines in a measured way.

A few small points

Ref 1 Kurtz is widely cited but is dated. 673% increase relates to a baseline of 2005. I recommend either omitting this - it doesn't add a lot - or citing more recent studies (e.g. Inacio 2017 TKR, Culliford 2015 UK, or others)

Page 3 Line 34. A useful extra reference would be the review by Kunutsor of 13 studies with 2004 infections in 177,618 patients shows RR for infection of 1.7 in RA (https://www.ncbi.nlm.nih.gov/pubmed/26938768)

Page 4 Line 52. Referencing has gone awry. 32 here should be 33 I think. Please check the referencing throughout although I think it is mainly OK.

Page 4 Line 63. Rewrite this as only one study (the RCT ref 39) is cited.

Page 5 Line 67. space after ) and remove a

Page 6 Line 93. "and the risk of death and cardiac events has doubled". If this is comparing the 2 studies, there is the risk that the populations differ.

Page 8. Orthopaedic surgeons are concerned with preventing complications for many reasons. There is a huge amount of research into preventing VTE and we should expect that implementation of treatments will have had some effect on reducing VTE in the knee and hip replacement population. This also relates to Line 205

Quality of written English

Please indicate the quality of language in the manuscript:

Acceptable
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.